Influence of hypercholesterolemia on serum antibodies against oxidized <scp>LDL</scp> in children and adolescents

Garoufi, Anastasia; Marmarinos, Antonios; Vraila, Venetia-Maria; Dimou, Stamatina; Pagoni, Athanasia; Vorre, Styliani; Paraskakis, I.; Gourgiotis, Dimitrios

doi:10.1111/ped.13501

Pediatrics International

2018

DOI: 10.1111/ped.13501

|View full text |Cite

Influence of hypercholesterolemia on serum antibodies against oxidized LDL in children and adolescents

Anastasia Garoufi

Antonios Marmarinos

Venetia-Maria Vraila

et al.

Abstract: In children and adolescents with hypercholesterolemia, total anti-oxLDL antibodies cannot serve as a marker for risk for atherosclerosis or for future cardiovascular disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 38 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis

Yi¹,

Wang²,

Jia³

et al. 2020

j biomed nanotechnol

View full text Add to dashboard Cite

We developed a vaccine formulation containing ApoB derived P210 peptides as autoantigens, retinoic acid (RA) as an immune enhancer, both of which were delivered using PLGA nanoparticles. The formula was used to induce an immune response in 12-week-old male Apoe–/– mice with pre-existing atherosclerotic lesions. The nanotechnology platform PRINT® was used to fabricate PLGA nanoparticles that encapsulated RA inside and adsorbed the P210 onto the particle surface. In this study, we demonstrated that immunization of Apoe–/– mice with the formulation was able to considerably attenuate atherosclerotic lesions, accompanied by increased P210 specific IgM and another oxidized lipid derived autoantigen, M2AA, specific IgG autoantibodies, and decreased the inflammatory response, as compared to the P210 group with Freund's adjuvant. Our formulation represents an exciting technology to enhance the efficacy of the P210 vaccine.

show abstract

Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis

Yi¹,

Wang²,

Jia³

et al. 2020

j biomed nanotechnol

View full text Add to dashboard Cite

show abstract

Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management

Sun

Wolska

Amar

et al. 2023

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Statins are the lipid-lowering therapy of choice for the prevention of atherosclerotic cardiovascular disease (ASCVD) but their effectiveness in lowering Low-Density Lipoprotein-Cholesterol (LDL-C) can substantially differ between individuals. In this mini-review, we describe the different causes for a suboptimal statin response and an algorithm for the diagnosis and clinical management of these patients. Evidence Acquisition A PubMed search, using terms “statin resistance”, “statin sensitivity”, “statin pharmacokinetics”, “cardiovascular disease”, and “lipid-lowering therapies” was performed. Published papers in the past 10 years that were relevant to the topic were examined to provide content for this mini-review. Evidence Synthesis Suboptimal lowering of LDL-C by statins is a major problem in the clinical management of patients and limits the value of this therapeutic approach. There are multiple causes of statin hypo-responsiveness with compliance being the most common explanation. Other causes, such as analytical issues with LDL-C measurement and the presence of common lipid disorders (Familial Hypercholesterolemia, elevated lipoprotein(a)(Lp(a)) and secondary dyslipidemias) should be excluded before considering primary statin resistance from rare genetic variants in lipoprotein-related or drug-metabolism genes. A wide variety of non-statin lipid-lowering drugs are now available and can be added to statins to achieve more effective LDL-C lowering. Conclusions The evaluation of statin hypo-responsiveness is a multi-step process that can lead to the optimization of lipid-lowering therapy for the prevention of ASCVD. It may also lead to the identification of distinct types of dyslipidemias that require specific therapies and/or the genetic screening of family members.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Influence of hypercholesterolemia on serum antibodies against oxidized LDL in children and adolescents

Abstract: In children and adolescents with hypercholesterolemia, total anti-oxLDL antibodies cannot serve as a marker for risk for atherosclerosis or for future cardiovascular disease.

Cited by 2 publications

References 38 publications

Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis

Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis

Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management

Contact Info

Product

Resources

About